TapewireFind a company

person · Reporting owner

ARSENAULT KAITLYN

Disclosed activity across 1 company

Tapewire entity
67270
SEC CIK
0001877242

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Skye Bioscience, Inc.SKYE · Entity 8098Chief Financial OfficerFebruary 06, 2026February 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Skye Bioscience, Inc.

Report date February 06, 2026 · Filed February 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2036-02-06Direct125,000 Reported balance After 2026-02-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000

F1: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 06, 2026 Filed Feb 9, 2026 20:54 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $0.82 $0.00
Disclosure

SEC source: 0001628280-26-006624 · wk-form4_1770688482.xml · derivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2036-02-06

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Read SEC document
February 24, 2025 Filed Feb 26, 2025 17:53 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0001516551-25-000018 · wk-form4_1740610387.xml · derivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-02-25

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning February 21, 2025.

Read SEC document
November 18, 2024 Filed Nov 19, 2024 21:57 UTC Skye Bioscience, Inc. SKYE · Entity 8098 SaleCommon Stock 43,206 $4.99 $215,597.94
Disclosure

SEC source: 0001516551-24-000117 · wk-form4_1732071425.xml · nonDerivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,342

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.

Read SEC document
November 18, 2024 Filed Feb 28, 2025 18:54 UTC Amendment Skye Bioscience, Inc. SKYE · Entity 8098 SaleCommon Stock 43,026 $4.99 $214,699.74
Disclosure

SEC source: 0001516551-25-000022 · wk-form4a_1740786879.xml · nonDerivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,522

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.98 to $5.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade.

Read SEC document
November 15, 2024 Filed Nov 19, 2024 21:57 UTC Skye Bioscience, Inc. SKYE · Entity 8098 SaleCommon Stock 190 $5.55 $1,054.50
Disclosure

SEC source: 0001516551-24-000117 · wk-form4_1732071425.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,548

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.

Read SEC document
November 15, 2024 Filed Feb 28, 2025 18:54 UTC Amendment Skye Bioscience, Inc. SKYE · Entity 8098 SaleCommon Stock 190 $5.55 $1,054.50
Disclosure

SEC source: 0001516551-25-000022 · wk-form4a_1740786879.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,548

F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.

Read SEC document
October 28, 2024 Filed Oct 30, 2024 20:32 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 125,000 $0.00 Strike: $5.15 $0.00
Disclosure

SEC source: 0001516551-24-000102 · wk-form4_1730334740.xml · derivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2034-10-27

F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the four year period beginning October 28, 2024.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 18:42 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $14.56 $0.00
Disclosure

SEC source: 0001516551-24-000012 · wk-form4_1709336528.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-03-01

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 18:42 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001516551-24-000012 · wk-form4_1709336528.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,738

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 06:15 UTC Amendment Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $14.56 $0.00
Disclosure

SEC source: 0001516551-24-000016 · wk-form4a_1709550894.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2034-03-01

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 06:15 UTC Amendment Skye Bioscience, Inc. SKYE · Entity 8098 GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001516551-24-000016 · wk-form4a_1709550894.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,738

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSU's will become fully vested.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
November 06, 2023 Filed Nov 6, 2023 20:29 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 32,053 $0.00 Strike: $3.50 $0.00
Disclosure

SEC source: 0001516551-23-000096 · wk-form4_1699320590.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,436

Underlying: Common Stock · 32,053 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Read SEC document
November 06, 2023 Filed Nov 6, 2023 20:29 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantCommon Stock 128,209 $0.00 $0.00
Disclosure

SEC source: 0001516551-23-000096 · wk-form4_1699320590.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,738

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
August 25, 2023 Filed Aug 29, 2023 18:53 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 3,345,530 $0.00 Strike: $0.01 $0.00
Disclosure

SEC source: 0001516551-23-000064 · wk-form4_1693349578.xml · derivative · entry 2

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,345,530

Underlying: Common Stock · 3,345,530 shares

Expires 2033-08-25

F3 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Read SEC document
August 25, 2023 Filed Aug 29, 2023 18:53 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantCommon Stock 13,382,118 $0.00 $0.00
Disclosure

SEC source: 0001516551-23-000064 · wk-form4_1693349578.xml · nonDerivative · entry 1

ARSENAULT KAITLYN · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,382,118

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 18:59 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantStock Option (Right to Buy) · Derivative 1,770,000 $0.00 Strike: $0.06 $0.00
Disclosure

SEC source: 0001516551-21-000027 · wf-form4_163969915831608.xml · derivative · entry 2

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,770,000

Underlying: Common Stock · 1,770,000 shares

Expires 2031-12-14

F3 · derivative.exercise_date: The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested.

Read SEC document
December 14, 2021 Filed Dec 16, 2021 18:59 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantCommon Stock 1,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001516551-21-000027 · wf-form4_163969915831608.xml · nonDerivative · entry 1

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
October 04, 2021 Filed Oct 5, 2021 20:42 UTC Skye Bioscience, Inc. SKYE · Entity 8098 GrantEmployee Stock Option (Right to Buy) · Derivative 1,600,000 $0.00 Strike: $0.09 $0.00
Disclosure

SEC source: 0001516551-21-000014 · wf-form4_163348095684882.xml · derivative · entry 1

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 1,600,000 shares

Expires 2031-10-04

F1 · derivative.exercise_date: 10% of the Options shall vest on October 4, 2021 (the "Vesting Start Date") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.